To determine if the reduction in TMPRSS2 activity via direct inhibition with Camostat mesilate combined with standard of care (SOC) treatment will increase the proportion of patients alive and free from respiratory failure at Day 28 in SARS-CoV-2 as compared to SOC treatment with placebo.
Drug: Camostat Mesilate
Given PO
Other Name: Foipan
Other: Standard of Care
At Investigator discretion
Inclusion Criteria:
- Laboratory confirmed SARS-CoV-2 infection
- Admitted to hospital for management of SARS-CoV-2
- Age ≥18
- Subject or legal representative able to give informed consent
- Ability to take all study drugs
- Respiratory status of 3 or greater on the WHO ordinal scale
- ALT or AST ≤5 x ULN
- Creatinine clearance ≥50 mL/min using the Cockroft-Gault formula
- Willingness to provide mandatory specimens for correlative research and banking
Exclusion Criteria:
- Women who are pregnant or breastfeeding
- Known hypersensitivity to the study drug, the metabolites or formulation excipient
Mayo Clinic in Arizona
Scottsdale, Arizona, United States
Tucson Medical Center
Tucson, Arizona, United States
Mayo Clinic in Florida
Jacksonville, Florida, United States
Alan H Bryce, M.D., Principal Investigator
Academic and Community Cancer Research United